GetTopicDetailResponse(id=dd898e10879, topicName=英國(guó)癌癥研究中心, introduction=英國(guó)癌癥研究中心, content=null, image=null, comments=4, allHits=1017, url=https://h5.medsci.cn/topic?id=87108, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=93215, tagList=[TagDto(tagId=93215, tagName=英國(guó)癌癥研究中心)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1623579, encodeId=45ab16235e98e, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英國(guó)癌癥研究中心#</a>, objectTitle=Bicycle Therapeutics宣布與英國(guó)癌癥研究中心合作開發(fā)新型腫瘤免疫學(xué)候選藥物——多價(jià)CD137激動(dòng)劑BT7401, objectType=article, longId=185937, objectId=58ff18593e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58ff18593e64, replyNumber=0, likeNumber=101, createdTime=2020-01-10, rootId=0, userName=yankaienglish, userId=1f6b20558327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58ff18593e64, moduleTitle=Bicycle Therapeutics宣布與英國(guó)癌癥研究中心合作開發(fā)新型腫瘤免疫學(xué)候選藥物——多價(jià)CD137激動(dòng)劑BT7401, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=58ff18593e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623578, encodeId=8a0716235e868, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英國(guó)癌癥研究中心#</a>, objectTitle=英國(guó)癌癥研究中心與Hummingbird聯(lián)合開發(fā)抗HER3單抗，以治療多種腫瘤并克服癌癥耐藥性, objectType=article, longId=177326, objectId=d5131e7326c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5131e7326c0, replyNumber=0, likeNumber=144, createdTime=2019-08-11, rootId=0, userName=yankaienglish, userId=1f6b20558327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5131e7326c0, moduleTitle=英國(guó)癌癥研究中心與Hummingbird聯(lián)合開發(fā)抗HER3單抗，以治療多種腫瘤并克服癌癥耐藥性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d5131e7326c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623577, encodeId=415216235e7fe, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英國(guó)癌癥研究中心#</a>, objectTitle=英國(guó)癌癥研究中心投資1400萬(wàn)英鎊在倫敦建立癌癥生物治療中心, objectType=article, longId=149084, objectId=fe671490840a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe671490840a, replyNumber=0, likeNumber=78, createdTime=2018-09-20, rootId=0, userName=yankaienglish, userId=1f6b20558327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe671490840a, moduleTitle=英國(guó)癌癥研究中心投資1400萬(wàn)英鎊在倫敦建立癌癥生物治療中心, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fe671490840a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623576, encodeId=b40c16235e6fc, content=<a href='/topic/show?id=dd898e10879' target=_blank style='color:#2F92EE;'>#英國(guó)癌癥研究中心#</a>, objectTitle=英國(guó)癌癥研究中心攜手Bicycle Therapeutics進(jìn)行實(shí)體瘤臨床試驗(yàn), objectType=article, longId=84998, objectId=d5c18499892, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5c18499892, replyNumber=0, likeNumber=81, createdTime=2016-12-23, rootId=0, userName=yankaienglish, userId=1f6b20558327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5c18499892, moduleTitle=英國(guó)癌癥研究中心攜手Bicycle Therapeutics進(jìn)行實(shí)體瘤臨床試驗(yàn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d5c18499892)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
